{"product_id":"valneva-business-model-canvas","title":"Valneva Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas for vaccine innovators - investor-ready insights \u0026amp; editable templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Valneva’s business model with our Business Model Canvas—three to five concise, investor-ready insights into how Valneva creates value, scales vaccines, and secures partnerships. Download the complete, editable Word and Excel files to benchmark, plan, and present with confidence. Purchase now to access all nine building blocks and practical analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Pfizer alliance co-develops and co-commercializes VLA15, combining Valneva’s vaccine expertise with Pfizer’s late-stage development and global commercialization scale. The agreement includes milestone payments, shared development costs and royalties linked to regulatory approvals and sales. As of 2024 the partnership is positioned to mitigate development risk and accelerate global market access for the Lyme vaccine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health funders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngagements with CEPI and public health agencies de-risk Valneva’s emerging infectious disease programs, leveraging CEPI’s mobilization of over $1.5 billion since 2017 to accelerate vaccine R\u0026amp;D. Non-dilutive funding underwrites clinical trials, manufacturing readiness and outbreak response, aligning Valneva’s portfolio with public health priorities and access provisions and strengthening credibility in neglected\/emerging pathogens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva works continuously with FDA, EMA, MHRA and 30+ national authorities for approvals and lifecycle management. Scientific advice and rolling reviews (used in multiple 2022–24 filings) accelerate timelines and evidence generation. Post-marketing safety commitments, including 15-day serious safety reports, are coordinated closely. Partnerships facilitate labeling, lot release and global registrations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMOs and suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCMOs and suppliers provide qualified antigen production, fill-finish, adjuvants and specialty components, with validated quality agreements in place to meet GMP standards.\u003c\/p\u003e\n\u003cp\u003eDual sourcing and formal quality agreements secure supply continuity and enable technical transfers that allow surge capacity within weeks to months when demand spikes.\u003c\/p\u003e\n\u003cp\u003eThese partnerships support cost control and scalability across Valneva products, reducing operational risk and shortening time-to-market.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003equalified partners for antigen, fill-finish, adjuvants\u003c\/li\u003e\n\u003cli\u003edual sourcing + quality agreements\u003c\/li\u003e\n\u003cli\u003etechnical transfers enable surge capacity\u003c\/li\u003e\n\u003cli\u003esupports cost control and scalability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlliances with wholesalers, specialty distributors and travel\/occupational health networks extend Valneva's reach into hospitals, pharmacies and vaccination centers globally, improving vaccine access. Joint demand planning with partners reduces stockouts and optimizes inventory turnover. Localized promotion and point-of-care education increase uptake in target markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistribution partnerships\u003c\/li\u003e\n\u003cli\u003eJoint demand planning\u003c\/li\u003e\n\u003cli\u003ePoint-of-care education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners support pivotal 2024 trials, over \u003cstrong\u003e1.5bn\u003c\/strong\u003e public funding and GMP surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships: Pfizer co-develops\/co-commercializes VLA15 (pivotal trials 2024); CEPI\/public agencies provide non-dilutive funding (CEPI mobilized \u0026gt;1.5bn since 2017); regulators (FDA\/EMA\/MHRA +30 authorities) enable rolling reviews; CMOs\/dual-sourced suppliers ensure GMP supply and surge capacity; distributors\/wholesalers expand market reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eCo-dev\/commercialize\u003c\/td\u003e\n\u003ctd\u003ePivotal trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEPI\u003c\/td\u003e\n\u003ctd\u003eFunding\/accelerator\u003c\/td\u003e\n\u003ctd\u003eSupports trials; \u0026gt;1.5bn mobilized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacture\/surge\u003c\/td\u003e\n\u003ctd\u003eDual sourcing, GMP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Valneva mapping the 9 BMC blocks to its vaccine-focused value propositions, R\u0026amp;D and manufacturing capabilities, regulatory and commercial channels, strategic partnerships, and revenue streams. It highlights competitive advantages, sector risks, and funding needs to support strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Valneva’s business model with editable cells to quickly pinpoint vaccine pipeline, revenue streams, and strategic risks; ideal for boardrooms or teams needing a concise, shareable snapshot that saves hours of formatting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva's Vaccine R\u0026amp;D focuses on discovery, antigen design and formulation across target pathogens, advancing candidates through preclinical validation where typical attrition rates reach 70–80% and immunogenicity optimization is core. Platform and adjuvant selection target safety-efficacy trade-offs, with adjuvants often boosting antibody titers 2–5x in studies. Pipeline prioritization weighs unmet needs against commercial potential and market size to allocate resources.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and execution of Phase 1–3 trials focus on safety, immunogenicity and efficacy, with Phase 3 cohorts typically ranging from several thousand to tens of thousands of participants. Global site management and centralized data systems ensure data integrity and GCP compliance across regions. Biostatistics and predefined interim analyses drive go\/no-go decisions and adaptive enrollment. Trials in endemic regions and diverse patient populations support broader, label-strengthening efficacy claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory affairs prepares IND\/CTA and BLA\/MAA dossiers and manages timely responses to agency queries, leveraging Valneva’s EC-approved COVID-19 vaccine VLA2001 (approved 2021) as a precedent. They coordinate inspections, pharmacovigilance plans and label negotiations across territories. Teams drive risk‑management and post‑approval commitments and ensure lifecycle compliance across markets. Activities support product approval and commercial access. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGMP manufacturing covers scale-up, validation and routine production of Valneva vaccines with stringent in-process controls, batch release testing and end-to-end cold-chain logistics to protect potency.\u003c\/p\u003e\n\u003cp\u003eTech transfers to internal lines or CMOs provide flexibility for surge capacity and regulatory compliance; continuous improvement programs target yield increases and lower cost per dose.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale-up: validation to routine GMP production\u003c\/li\u003e\n\u003cli\u003eQuality: in-process controls \u0026amp; batch release testing\u003c\/li\u003e\n\u003cli\u003eLogistics: validated cold-chain management\u003c\/li\u003e\n\u003cli\u003eFlexibility: internal\/CMO tech transfers\u003c\/li\u003e\n\u003cli\u003eEfficiency: continuous yield \u0026amp; cost improvements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarket access combines health-economic modeling, pricing and reimbursement strategies aligned to 2024 HTA requirements to demonstrate value and secure favorable tariffs. Active engagement with NITAGs and procurement agencies drives recommendations and inclusion in national schedules. Medical education and KOL development increase clinical uptake while forecasting and tender participation secure contracted volumes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHE modeling aligned to 2024 HTA\u003c\/li\u003e\n\u003cli\u003eNITAG\/procurement engagement\u003c\/li\u003e\n\u003cli\u003eKOL-led medical education\u003c\/li\u003e\n\u003cli\u003eForecasting + tender participation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine R\u0026amp;D: \u003cstrong\u003e70-80%\u003c\/strong\u003e preclinical attrition, GMP scale-up and HTA access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVaccine R\u0026amp;D: discovery, antigen\/formulation, preclinical attrition 70–80% and adjuvants boosting titers ~2–5x. Clinical: Phase 1–3 focusing safety\/immunogenicity; Phase 3 cohorts range from several thousand to tens of thousands. Manufacturing: GMP scale‑up, tech transfers to CMOs, cold chain and batch testing. Market access: HE modeling aligned to 2024 HTA, NITAG engagement and tendering.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical attrition\u003c\/td\u003e\n\u003ctd\u003e70–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjuvant titer boost\u003c\/td\u003e\n\u003ctd\u003e2–5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 size\u003c\/td\u003e\n\u003ctd\u003eseveral thousand–tens of thousands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTA alignment\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you’re previewing is the actual Valneva Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file—complete, formatted, and ready to edit. The full deliverable is provided in Word and Excel so you can present, customize, or share it immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161484669305,"sku":"valneva-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/valneva-business-model-canvas.png?v=1762693747","url":"https:\/\/portersfiveforce.com\/products\/valneva-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}